Curis, Inc.
61 Moulton Street
Cambridge
Massachusetts
02138
Tel: 617-876-0086
Fax: 617-876-0866
Website: http://www.curis.com/
478 articles with Curis, Inc.
-
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
5/12/2022
Curis, Inc. announced that multiple abstracts have been accepted for presentation at the upcoming European Hematology Association 2022 Hybrid Congress, which will be held virtually and in-person in Vienna on June 9-12, 2022.
-
Curis Reports First Quarter 2022 Financial Results and Business Update
5/5/2022
Curis, Inc. reported its financial results for the first quarter ended March 31, 2022 and provided business updates.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
4/11/2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's TakeAim Lymphoma study (NCT03328078).
-
Curis, a biotech company that develops treatments for cancer, has announced that the FDA has placed a partial clinical hold on its TakeAim lymphoma study.
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Apr 07, 2022
4/7/2022
Curis, Inc. announced that on April 1, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 380,850 shares of Curis common stock to seven new employees, with a grant date of April 1, 2022.
-
Curis to Present at 21st Annual Needham Virtual Healthcare Conference
4/5/2022
Curis, Inc. today announced that James Dentzer , President and Chief Executive Officer of Curis, will present a company overview at the 21st Annual Needham Virtual Healthcare Conference.
-
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
4/4/2022
Curis, Inc. announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the Company's TakeAim Leukemia Phase 1/2a study.
-
Curis Announces Gastroenterology Publication of Encouraging Preclinical Data of Emavusertib in Pancreatic Cancers
3/7/2022
Curis, Inc. (NASDAQ: CRIS), today announced that a manuscript has been published in the peer-reviewed journal Gastroenterology, authored by Curis collaborators at Washington University School of Medicine in St. Louis, on the role of IRAK4 in pancreatic ductal adenocarcinoma (PDAC) and the preclinical efficacy of emavusertib (CA-4948).
-
Curis Reports Fourth Quarter and Year End 2021 Financial Results
2/24/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the fourth quarter ended December 31, 2021.
-
Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022
2/17/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the close of U.S. markets.
-
Curis to Present at Upcoming Healthcare Conferences - Jan 20, 2022
1/20/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that James Dentzer, President and Chief Executive Officer, will participate in the following upcoming conferences:
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Jan 07, 2022
1/7/2022
Curis, Inc. announced that on January 3, 2022, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 224,700 shares of Curis common stock to eleven new employees, with a grant date of January 3, 2022.
-
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy
1/6/2022
Curis, Inc. today announced positive updated clinical data from the ongoing open label Phase 1/2 dose escalation and expansion study of CA-4948.
-
Curis to Present at H.C. Wainwright BioConnect Conference
1/3/2022
Curis, Inc. today announced that James Dentzer, President and Chief Executive Officer of Curis, will present at the H.C. Wainwright BioConnect Conference.
-
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
1/3/2022
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the appointment of three new executives to its management team.
-
Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF
12/15/2021
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that it has been selected for addition to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF.
-
Curis Appoints John A. Hohneker, M.D. To Board Of Directors
12/6/2021
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced the appointment of John A. Hohneker, M.D. to its Board of Directors.
-
Curis Reports Third Quarter 2021 Financial Results and Business Update
11/9/2021
Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported its financial results for the third quarter ended September 30, 2021 and provided business updates.
-
Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/9/2021
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced a poster presentation with new preclinical data for CI-8993, a first-in-class monoclonal antibody VISTA antagonist, at the Society for Immunotherapy of Cancer's 36th Annual Meeting.